Pharmaceutical Industry in China 2015-2020

Dublin, July 21, 2015 (GLOBE NEWSWIRE) -- Research and Markets ( has announced the addition of the "Pharmaceutical Industry in China to 2020: An In Depth Analysis of Multinational and Chinese Biopharma Companies, Industry Trends, Environment, Regulation, Market Drivers, Restraints, Opportunities & Challenges" report to their offering.

This report tackles not only global pharmaceutical company interest in China but also home grown companies and their battle for position. The business environment in which they compete is analysed as are key drivers, constraints, challenges and opportunities.

The Chinese Pharmaceutical market is currently the second greatest pharma market globally, after the US and in 2014 was worth $105 billion. It is forecast to increase dramatically to $200 billion by 2020 and increase its dominance as a leading player in Asia.

This report describes the current therapeutics that are propelling the biopharmaceutical market in China. It examines the current economic climate and how China compares to other emerging markets and also evolved markets such as the US and Europe. Current developments relating to patent expirations, government funding, and regulations are discussed. The emerging trends that appear in key sub-markets such as generics, oncology, diabetes and vaccines are elucidated and analysed.

This study reveals market figures of the overall Chinese pharmaceutical market and sub-markets. Forecast projections and future growth rates are provided to give the reader a forthcoming perspective of this growing industry. The study also provides a comprehensive financial and product review of key players in the biopharmaceutical industry in China. Strategic drivers and restraints of this market are revealed and market opportunities and challenges are identified.

In summary, the Chinese biopharmaceutical market has huge opportunities for growth. This industry will significantly affect the international healthcare market and has enormous potential for investment.

Key Topics Covered:

1.0 Summary

2.0 Chronic Disease Prevalence Statistics

3.0 Business Environment

4.0 Chinese Pharmaceutical Market

5.0 Government and Regulation Environment

6.0 China - Second Largest Pharma Market 2014

7.0 Global Pharmaceutical Companies Interest in China

8.0 Chinese Pharmaceutical Companies

9.0 Drivers, Restraints, Challenges and Opportunity Analysis

Companies Mentioned

- Amoytop Biotech
- Active Pharmaceutical Products
- Beijing Continent Pharmaceuticals
- FusoGen Pharmaceuticals
- Shanghai Huaguan Biochip
- SiBiono GeneTech
- Abbott
- AstraZeneca
- Boehringer Ingelheim
- Eli Lilly
- GlaxoSmithKline
- Johnson & Johnson Medical
- Merck
- Novartis
- Pfizer
- Roche

For more information visit


Contact Data